Virus-like particles (VLPs) are a class of subunit vaccines that differentiate themselves from
soluble recombinant antigens by stronger protective immunogenicity associated with the …

The development of new adjuvants for human vaccines has become an expanding field of
research in the last thirty years, for generating stronger vaccines capable of inducing …

Recurrent outbreaks of highly pathogenic avian influenza virus pose the threat of pandemic
spread of lethal disease and make it a priority to develop safe and effective vaccines …

Virus‐like particles (VLPs) mimic the whole construct of virus particles devoid of viral
genome as used in subunit vaccine design. VLPs can elicit efficient protective immunity as …

The last big outbreaks of Ebola fever in Africa, the thousands of avian influenza outbreaks
across Europe, Asia, North America and Africa, the emergence of monkeypox virus in …

Vaccination continues to be the main approach to protect animals from infectious diseases.
Until recently, all licensed vaccines were developed using conventional technologies …

Virus-like particle (VLP) technology is a promising approach for the construction of novel
vaccines, diagnostic tools, and gene therapy vectors. Initially, VLPs were primarily derived …

The strategy of World Health Organization is to develop efficient and inexpensive vaccine
against various infectious diseases amongst children's population. Vaccination is …

Vaccines against viral disease have traditionally relied on attenuated virus strains or
inactivation of infectious virus. Subunit vaccines based on viral proteins expressed in …

Vaccination is one of the most effective and cost-benefit interventions that prevent the
mortality and reduce morbidity from infectious pathogens. However, the licensed influenza …